SOUTH SAN FRANCISCO, Calif., Jan. 16, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced that on January 14, 2013, Nasdaq notified the Company that it regained compliance with the minimum $1.00 per share closing bid price requirement for continued listing. As a result of satisfying the minimum bid price requirement, this matter is now closed.
